| Restate the current standard of care options for the first-line mCRC therapy, using chemotherapy in combination with targeted agents |
|
|
|
|
|
| Identify which patients should undergo mutation testing, and understand how these results impact selection of therapy |
|
|
|
|
|
| Assess the potential utility of other predictive biomarkers |
|
|
|
|
|
| Update the incorporation of biologics into the management of colorectal cancer |
|
|
|
|
|
| Discuss indications for and potential benefits of radiation therapy in patients with unresectable disease |
|
|
|
|
|
| Compare the potential benefits and limitation of oral cancer therapy for mCRC |
|
|
|
|
|
